RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy Oct 18, 2021
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor Oct 12, 2021
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents Sep 16, 2021
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies Jul 7, 2021
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies May 19, 2021
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map May 11, 2021
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan) May 3, 2021
RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference Feb 18, 2021
Healthcare Roundup – Sesen price target raised on prospects for bladder cancer therapy; Sundial makes $22M investment in cannabis edibles company Indiva Feb 16, 2021 Life Science
